Translate page


David Yeung 3Devendra HiwaseAgnes YONG w labcoat1

Dr David Yeung        Dr Devendra Hiwase     Dr Agnes Yong



Session 2: TKI resistance / failure

  • When frontline therapy fails 
    (Dr David Yeung)
  • CML - beyond chronic phase
    (Dr Devendra Hiwase)
  • Allograft - still a role in CML?
    (Dr Agnes Yong)



David Yeung 3



When frontline therapy fails
Dr David Yeung- SA Pathology, University of Adelaide

  • LASOR - failure to achieve 2009 ELN goals
  • TIDEL II - failure to achieve optimal ELN 2013 treatment goals
  • ENESTcmr - failure to achieve deep molecular response
  • Ponatinib - drug of last resort?
  • Asciminib (ABL001) - rising star?


Devendra Hiwase  

CML - Beyond chronic phase?
Dr Devendra Hiwase - SA Pathology, University of Adelaide

  • CML in accelerated phase (including patient case)
    • First-line IM in patients with newly diagnosed AP 
    • NIL following imatinib resistance or intolerance
    • DAS after imatinib failure
    • IM versus stem cell transplantation 
    • PON in patients with CML and PH+ ALL resistant/intolerant to IM
    • Treatment strategy recommendations for CML in AP
  • CML in blast crisis (including patient case)
    • Survival of CML blast crisis patients
    • Prognostic factors and survival outcomes in patients with CML in blast crisis
    • Further treatment options

Agnes YONG w labcoat1


Allograft - Still a role in CML?
Dr Agnes Yong - SA Pathology, University of Adelaide

  • Historic overview of allogeneic stem cell transplantation in CML
  • Survival rates after transplantation
  • EBMT score for alloSCT in CML?
  • Which CML patient needs transplant?
  • Which conditioning regime for alloSCT?
  • Role of TKI's after transplant
  • Summary